Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism.

Doehle BP, Chang K, Rustagi A, McNevin J, McElrath MJ, Gale M Jr.

J Virol. 2012 Aug;86(16):8367-74. doi: 10.1128/JVI.00423-12. Epub 2012 May 16.

2.

Vpu-deficient HIV strains stimulate innate immune signaling responses in target cells.

Doehle BP, Chang K, Fleming L, McNevin J, Hladik F, McElrath MJ, Gale M Jr.

J Virol. 2012 Aug;86(16):8499-506. doi: 10.1128/JVI.00424-12. Epub 2012 May 30.

3.

HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3.

Manganaro L, de Castro E, Maestre AM, Olivieri K, García-Sastre A, Fernandez-Sesma A, Simon V.

J Virol. 2015 Oct;89(19):9781-90. doi: 10.1128/JVI.01596-15. Epub 2015 Jul 15.

4.

HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor.

Park SY, Waheed AA, Zhang ZR, Freed EO, Bonifacino JS.

J Biol Chem. 2014 Dec 19;289(51):35102-10. doi: 10.1074/jbc.M114.597062. Epub 2014 Oct 28.

5.

HIV-1 Vpu does not degrade interferon regulatory factor 3.

Hotter D, Kirchhoff F, Sauter D.

J Virol. 2013 Jun;87(12):7160-5. doi: 10.1128/JVI.00526-13. Epub 2013 Apr 3.

6.

Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells.

Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M Jr.

J Virol. 2009 Oct;83(20):10395-405. doi: 10.1128/JVI.00849-09. Epub 2009 Aug 12.

7.

Emerging role of the host restriction factor tetherin in viral immune sensing.

Hotter D, Sauter D, Kirchhoff F.

J Mol Biol. 2013 Dec 13;425(24):4956-64. doi: 10.1016/j.jmb.2013.09.029. Epub 2013 Sep 26. Review.

PMID:
24075872
8.

Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release.

Jafari M, Guatelli J, Lewinski MK.

J Virol. 2014 May;88(9):5062-78. doi: 10.1128/JVI.03472-13. Epub 2014 Feb 26.

9.

Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING.

Trotard M, Tsopoulidis N, Tibroni N, Willemsen J, Binder M, Ruggieri A, Fackler OT.

J Virol. 2015 Dec 9;90(4):2064-76. doi: 10.1128/JVI.02966-15.

10.

HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.

Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V.

PLoS Pathog. 2009 Sep;5(9):e1000574. doi: 10.1371/journal.ppat.1000574. Epub 2009 Sep 4.

11.

Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells.

Lam E, Falck-Pedersen E.

J Virol. 2014 Dec;88(24):14426-39. doi: 10.1128/JVI.02608-14. Epub 2014 Oct 8.

12.

Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection.

Mlcochova P, Apolonia L, Kluge SF, Sridharan A, Kirchhoff F, Malim MH, Sauter D, Gupta RK.

Virology. 2015 Aug;482:72-8. doi: 10.1016/j.virol.2015.03.015. Epub 2015 Mar 30.

13.
14.

HIV-1 evades innate immune recognition through specific cofactor recruitment.

Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, Hilditch L, Jacques DA, Selwood DL, James LC, Noursadeghi M, Towers GJ.

Nature. 2013 Nov 21;503(7476):402-5. doi: 10.1038/nature12769. Epub 2013 Nov 6.

15.

HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K.

J Biol Chem. 2009 Dec 11;284(50):35060-72. doi: 10.1074/jbc.M109.058305. Epub 2009 Oct 16.

16.

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.

Pattabhi S, Wilkins CR, Dong R, Knoll ML, Posakony J, Kaiser S, Mire CE, Wang ML, Ireton RC, Geisbert TW, Bedard KM, Iadonato SP, Loo YM, Gale M Jr.

J Virol. 2015 Dec 16;90(5):2372-87. doi: 10.1128/JVI.02202-15.

17.

HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.

Bolduan S, Hubel P, Reif T, Lodermeyer V, Höhne K, Fritz JV, Sauter D, Kirchhoff F, Fackler OT, Schindler M, Schubert U.

Virology. 2013 Jun 5;440(2):190-203. doi: 10.1016/j.virol.2013.02.021. Epub 2013 Mar 22.

18.

HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins.

Haller C, Müller B, Fritz JV, Lamas-Murua M, Stolp B, Pujol FM, Keppler OT, Fackler OT.

J Virol. 2014 Dec;88(24):14241-57. doi: 10.1128/JVI.02333-14. Epub 2014 Oct 1.

19.

Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.

Gupta RK, Hué S, Schaller T, Verschoor E, Pillay D, Towers GJ.

PLoS Pathog. 2009 May;5(5):e1000443. doi: 10.1371/journal.ppat.1000443. Epub 2009 May 22.

20.

HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions.

Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J.

J Biol Chem. 2012 Jan 2;287(1):58-67. doi: 10.1074/jbc.M111.296772. Epub 2011 Nov 9.

Items per page

Supplemental Content

Write to the Help Desk